同步寡转移非小细胞肺癌的定义:共识报告
欧洲多学科共识组通过系统综述、病例和调查制定同步寡转移NSCLC的定义与诊断标准,提出最多5个转移灶、3个器官且不将纵隔淋巴结计入转移部位,并明确影像与活检要求,以标准化未来临床试验入组。
要点
- 同步寡转移NSCLC定义适用于所有肿瘤部位可根治性治疗且毒性可接受者。
- 转移灶上限为5个、累及器官上限为3个,纵隔淋巴结不计为转移部位。
- FDG PET-CT和脑影像为必需,孤立肝转移建议肝脏MRI,孤立胸膜转移推荐胸腔镜和活检。
核心结论
- 制定了同步寡转移NSCLC的多学科共识定义和分期标准,有助于标准化未来临床试验的入组标准。
研究设计与样本
- 泛欧洲多学科共识组基于当前争议构建共识问题,从调查、病例和系统综述中提取定义,并在共识会议上形成声明。
主要发现
- 当所有肿瘤部位可根治性治疗且毒性可接受时,同步寡转移NSCLC的定义具有相关性。
- 基于综述提出最多5个转移灶和3个器官,纵隔淋巴结受累不计为转移部位。
关键数值与推荐
- FDG PET-CT和脑影像被认为是必需的。
- 孤立肝转移建议专用肝脏MRI扫描。
- 孤立胸膜转移推荐胸腔镜和同侧远隔胸膜部位活检。
- 纵隔分期最低要求为FDG PET-CT,若影响治疗策略则推荐病理确认。
- 孤立转移部位活检是强制性的,除非多学科团队认为风险大于获益。
临床怎么用
- 临床可依据该共识判断同步寡转移NSCLC患者是否适合根治性治疗。
- 诊断分期应包含FDG PET-CT和脑影像,并按转移部位补充相应影像或活检。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Improved outcome has been shown in patients with synchronous oligometastatic (sOM) NSCLC when treated with radical intent. As a uniform definition of sOM NSCLC is lacking, we developed a definition and diagnostic criteria by a consensus process. METHODS: A pan-European multidisciplinary consensus group was established. Consensus questions were built on the basis of current controversies, and definitions were extracted from a survey, cases and a systematic review. This statement was formulated during a consensus meeting. RESULTS: It was determined that definition of sOM NSCLC is relevant when a radical treatment that may modify the disease course (leading to long-term disease control) is technically feasible for all tumor sites with acceptable toxicity. On the basis of the review, a maximum of five metastases and three organs was proposed. Mediastinal lymph node involvement was not counted as a metastatic site. Fludeoxyglucose F 18 positron emission tomography-computed tomography and brain imaging were considered mandatory. A dedicated liver magnetic resonance imaging scan was advised for a solitary liver metastasis, and thoracoscopy and biopsies of distant ipsilateral pleural sites were recommended for a solitary pleural metastasis. For mediastinal staging, fludeoxyglucose F 18 positron emission tomography-computed tomography was deemed the minimum requirement, with pathological confirmation recommended if this influences the treatment strategy. Biopsy of a solitary metastatic location was mandated unless the multidisciplinary team is of the opinion that the risks outweigh the benefits. CONCLUSION: A multidisciplinary consensus statement on the definition and staging of sOM NSCLC has been formulated. This statement will help to standardize inclusion criteria in future clinical trials.
引用
- Dingemans AC, Hendriks LEL, Berghmans T, et al. Definition of Synchronous Oligometastatic Non-Small Cell Lung Cancer-A Consensus Report. J Thorac Oncol. 2019. PMID: 31398540. doi:10.1016/j.jtho.2019.07.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。